September 20th, 2016
11 am to 12 pm EST

Sponsored by

Webinar Description:

How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights. To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized.

Learning Objectives:

• 10 years of personalized medicine evidence-based insights from Diaceutics
• The latest in data and research on PD-L1 testing, adoptions, kits and labels
• How to prepare for targeted therapy launches
• Laboratory mapping and optimal lab footprints based on therapy, test and target prescribers

Complimentary Report

Diaceutics will provide a complimentary copy of their new PD-L1 Predictive Insights Report to only those attendees joining the webinar on September 20th.

Speakers:

Peter Keeling

CEO

Diaceutics Group

Peter has over 29 years' experience in international healthcare, first at GSK and Diagnology and then at Diaceutics. Peter has directly initiated and managed the launch of four pharmaceutical, seven OTC and five diagnostic products in addition to three joint ventures and two major joint corporate marketing campaigns. In addition to Peter's extensive operational experience in the US, he also has substantial experience running operations in all the key healthcare markets of the world, including Germany, Indonesia the UK and Japan. Since founding Diaceutics, Peter has combined the need for a standardized and structured process to effectively commercialize and launch companion diagnostics alongside drug development with a group of companies providing customized commercialization services to the pharmaceutical industry Peter has spent two extended periods in applied industrial research, including a year at MIT's Pharmaceutical Program at the Sloan School of Management in Boston and is considered a thought leader in personalized medicine commercialization.

Ryan Keeling

Chief Operating Officer

Diaceutics Group

In his role as Chief Operating Office of the Diaceutics Group, Ryan is responsible for overseeing the operations of company and its divisions. Ryan previously lead the Labceutics division, leading the development of the division as a unique implementation service and harnessing global laboratory partnerships to improve testing infrastructure in support of personalized therapies Before joining Diaceutics, Ryan had developed a reputation as a leader in the software industry through eight years’ experience in Ireland’s telecoms industry. Ryan has significant experience in delivering core network telephony and application-based solutions, and in managing offshore development centers for global network operators such as France Telecom, Sprint, AT&T and Aepona.

Mark Reis, MBA

EVP Business Development

Diaceutics Group

Mark has spent the past 17 years focused on healthcare business development and marketing at an international level within the pharmaceutical, biotechnology, healthcare informatics and personalized medicine industries. His previous positions at Medco, DNA Direct, LumaSense Technologies, Inc., Philips Medical Systems, Stentor Inc. and Forbes Medi-tech, included wide-ranging responsibilities from business development, marketing strategy and communications, and sales operations to investor relations and integrated marketing. Mark holds a Bachelor or Arts from the University of Western Ontario and an M.B.A from New York University Stern School of Business.